Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A method of monitoring Plasmodium falciparum viability ex vivo was used to compare the ability of different antimalarial drugs to arrest the progression of young parasites to mature, potentially damaging stages. Neither pyrimethamine-sulfadoxine nor quinine, the treatment of choice for severe, life-threatening malaria, had a demonstrable effect on circulating parasites during the first 24 hr of therapy. In contrast, in vivo exposure to halofantrine for as little as six hours was sufficient to arrest parasite development. The method of assessing ex vivo parasite viability permits a comparison of antimalarial drug action at a time that may be critical for the therapy of life-threatening disease. If parenteral formulations of halofantrine prove to be safe and effective, they may have a role in the therapy of severe malaria.

Original publication

DOI

10.4269/ajtmh.1993.49.106

Type

Journal article

Journal

Am J Trop Med Hyg

Publication Date

07/1993

Volume

49

Pages

106 - 112

Keywords

Animals, Antimalarials, Drug Combinations, Drug Therapy, Combination, Humans, Malaria, Falciparum, Phenanthrenes, Plasmodium falciparum, Pyrimethamine, Quinine, Sulfadoxine, Time Factors